PIŚMIENNICTWO
1. Almansori M., Kovithavongs T., Qarni M.U.: Cyclooxygenase-2 inhibitor-associated minimal change disease. Clin Nephrol., 2005, 63, 381-384. – 2. Arakawa T., Nakamura A., Fukuda T., Higuchi K., Nakamura H., Kobayashi K.: In vitro adaptive cytoprotection in gastric cells isolated from rat stomach. J Clin Gastroenterol., 1990, 12, 1, 32-38. – 3. Bergh M.S., Budsberg S.C.: The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med., 2005, 19, 633-643. – 4. Bjarnason I., Hayllar J., MacPherson A.J., Russell A.S.: Side effects of nonsteroidal antiinflammatory drugs on the small and large intestine in humans. Gastroenterol., 1993, 104, 1832-1847. – 5. Black S.C., Brideau C., Cirino M., Belley M., Bosquet J., Chan C.C., Rodger I.W.: Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs. J Cardiovasc Pharmacol., 1998, 32, 686-694. – 6. Brzozowski T., Konturek P.C., Konturek S.J., Sliwowski Z., Pajdo R., Drozdowicz D., Ptak A., Hahn E.G.: Classic NSAID and selective cyclooxygenase COX-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tec., 2001, 53, 343-353. – 7. Clark T.P., Chieffo C., Huhn J.C., Nimz E.L., Wang C., Boy M.G.: The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. J Vet Pharmacol Ther., 2003, 26, 3, 187-192. – 8. Deneuche A.J., Dufayet C., Goby L., Fayolle P., Desbois C.: Analgesic comparison of meloxicam or ketoprofen for orthopedic surgery in dogs. Vet Surg., 2004, 33, 650-660.• – 9. Dow S.W., Rosychuk R.A.W., McChesney A.E., Curtis C.: Effects of flunixin and flunixin plus prednisone on the gastrointestinal tract of dogs. Am J Vet Res., 1990, 51, 1131-1138. – 10. Esteve, J.B., Launay-Vacher V., Brocheriou I., Grimaldi A., Izzedine H.: COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin Nephrol., 2005, 63, 385-389.
11. Forsyth S.F., Guilford W.G., Haslett S.J., Godfrey J.: Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract., 1998, 39, 421-424. – 12. Fujimori S., Gudis K., Sakamoto Ch.: A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury. Pharmaceut., 2010, 3, 1187-1201. – 13. Fujimori, S., Seo T., Gudis, K., Ehara A., Kobayashi T., Mitsui K., Yonezawa M., Tanaka S., Tatsuguchi A., Sakamoto C.: Prevention of nonsteroidal anti-inflammatory drug-induced small intestinal injury by prostaglandin: A pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc., 2008, 69, 1339-1346. – 14. Giraudel J.M., King J.N., Jeunesse E.C., Lees P., Toutain P.L.: Use of a pharmacokinetic pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib. J Vet Pharmacol Ther., 2009, 32, 18-30. – 15. Giraudel J.M., Toutain P.L., Lees P.: Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. Am J Vet Res., 2005, 66, 700-709. – 16. Hazewinkel H.A.W., van den Brom W.E., Theijise L.F.H., Pollmeier M., Hanson P.D.: Reduced dosage of ketoprofen for the short-term and long-term treatment of joint pain in dogs. Vet Rec., 2003, 152, 11-14. – 17. Jackson L.M., Wu K.C., Mahida Y.R., Jenkins D., Hawkey C.J.: Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut, 2000, 47, 762-770. – 18. Khan K.N., Venturini C.M., Bunch R.T., Brassard J.A., Koki A.T., Morris D.L., Trump B.F., Maziasz T.J., Alden C.L.: Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol., 1998, 26, 612-620. – 19. King J.N., Dawson J., Esser R.E., Fujimoto R., Kimble E.F., Maniara W., Marshall P.J., O’Byrne L., Quadros E., Toutain P.L. Lees P.: Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. J Vet Pharmacol Ther., 2009, 32, 1-17. – 20. King J.N., Rudaz C., Borer L., Jung M., Seewald W., Lees P.: In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Res Vet Sci., 2010, 88, 497-506.
21. Kleinschmidt S., Meneses F., Nolte I., Hewicker-Trautwein M.: Retrospective study on the diagnostic value of full-thickness biopsies from the stomach and intestines of dogs with chronic gastrointestinal disease symptoms. Vet Pathol., 2006, 43, 1000-1003. – 22. Lanas A.: Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am J Med Sci., 2009, 338, 96-106. – 23. Lascelles B.D.X., Blikslager A.T., Fox S.M., Reece D.: Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases 2002-2003. JVMA, 2005, 227, 1112-1117. – 24. Luna S.P.L., Basilio A.C., Steagall P.V.M., Machado L.P., Moutinho F.Q., Takahira R.K., Brandao C.V.S.: Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen and meloxicam in dogs. Am J Vet Res., 2007, 68, 258-264. – 25. Mahmud T., Rafi S.S., Scott D.L., Wrigglesworth J.M., Bjarnason I.: Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum., 1996, 39, 1998-2003. – 26. Maiden L., Thjodleifsson B., Theodors A., Gonzalez J., Bjarnason I.: A quantitative analysis of NSAID-induced small bowel pathology by capsule entoscopy. Gastroenterol., 2005, 128, 1172-1178. – 27. Mathews K.A., Doherty T., Dyson D.H., Wilcock B., Valliant A.: Nephrotoxicity in dogs associated with methoxyflurane anesthesia and flunixin meglumine analgesia. Can Vet J., 1990, 31, 11, 766-771. – 28. Moore L.E.: The advantages and disadvantages of endoscopy. Clin Tech Small Anim Pract., 2003, 18, 4, 250-300. – 29. Peterson K.D., Keefe T.J.: Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs. JAVMA, 2004, 225, 1056-1060. – 30. Radi Z.A., Khan N.K.: Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Toxicol Pathol., 2006, 58, 2-3, 163-173.
31. Reed S.: Nonsteroidal anti-inflammatory drug-induced duodenal ulceration and perforation in a mature rottweiler. Can Vet J., 2002, 43, 971-972. – 32. Sakamoto C., Sugano K., Ota S., Sakaki N., Takahashi S., Yoshida Y., Tsukui T., Osawa H., Sakurai Y., Yoshino J., Mizokami Y., Mine T., Arakawa T., Kuwayama H., Saigenji K., Yakabi K., Chiba T., Shimosegawa T., Sheehan J.E., Perez-Gutthann S., Yamaguchi T., Kaufman D.W., Sato T., Kubota K., Terano A.: Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol., 2006, 62, 765-772. – 33. Singh G., Triadafilopoulos G.: Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract., 2005, 59, 10, 1210-1217. – 34. Wilson J.E., Chandrasekharan N.V., Westover K.D., Eager K. B., Simmons D.L.: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal antiinflammatory drugs. Am J Vet Res., 2004, 65, 810-818. – 35. Wooten J.G., Lascelles B.D., Cook V.L., Law J.M., Blikslager A.T.: Evaluation of the relationship between lesions in the gastroduodenal region and cyclooxygenase expression in clinically normal dogs. Am J Vet Res., 2010, 71, 6, 630-365.
